Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;99(7):750-755.
doi: 10.1111/aos.14731. Epub 2020 Dec 30.

The impact of advanced age-related macular degeneration on the National Eye Institute's Visual Function Questionnaire-25

Jennifer L Patnaik  1 , Anne M Lynch  1 , Paula E Pecen  1 , Maria Jasso  1 , Kara Hanson  1 , Marc T Mathias  1 , Alan G Palestine  1 , Naresh Mandava  1
Affiliations
Free article

The impact of advanced age-related macular degeneration on the National Eye Institute's Visual Function Questionnaire-25

Jennifer L Patnaik et al. Acta Ophthalmol. 2021 Nov.
Free article

Abstract

Purpose: To assess visual function among patients diagnosed with age-related macular degeneration (AMD) by stage of disease and laterality.

Methods: This is a cross-sectional cohort study of 739 AMD patients and their responses to the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) at time of study enrolment. Patients with AMD were categorized into Early/Intermediate AMD and three groups of advanced AMD: (i) neovascular AMD (NV), (ii) geographic atrophy (GA) and (iii) Both Advanced forms. These three advanced stages were further stratified into unilateral or bilateral advanced disease. Mean composite scores and subscale scores for 12 different areas were based on a 100-point scale with the lowest and highest possible scores set at 0 and 100, respectively. Scores for the advanced AMD groups were compared with Early/Intermediate AMD using general linear modelling.

Results: A total of 739 AMD patients (294 Early/Intermediate, 115 GA, 168 NVAMD and 162 Both Advanced) were included in the analysis. Mean composite scores were highest among Early/Intermediate patients (89.9), followed by patients diagnosed with unilateral disease in the Both Advanced (88.0) and NV (86.1) groups. Mean composite scores were similar for bilateral NV (82.9) and unilateral GA (81.7), and mean scores were lowest for the bilateral GA (71.3) and bilateral Both Advanced (68.5) groups. In general, this pattern persisted across the twelve subscales as well. Subscale scores ranged from a low of 35.1 for driving among bilateral Both Advanced patients to a high of 99.2 for colour vision among patients with unilateral Both Advanced. Overall, patients with unilateral advanced disease consistently had higher mean scores than their bilateral counterparts. The largest difference was 19.5 composite score points between the unilateral and bilateral Both Advanced groups, there was a difference of 10.4 points between the GA groups, and a relatively small difference of 3.2 points between the NV groups.

Conclusions: We found large differences in visual function as reported from the VFQ-25 across the different types of advanced stage AMD groups and number of eyes affected with advanced AMD. These findings demonstrate the importance of accounting for the type and number of eyes affected by advanced stage AMD.

Keywords: age-related macular degeneration; choroidal neovascularization; geographic atrophy; visual function questionnaire.

PubMed Disclaimer

References

    1. Bressler NM, Chang TS, Varma R et al. (2013): Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology 120: 160-168.
    1. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR & Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group (2007): Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125: 1460-1469.
    1. Coleman AL, Yu F, Ensrud KE, Stone KL, Cauley JA, Pedula KL, Hochberg MC & Mangione CM (2010): Impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am J Ophthalmol 150: 683-691.
    1. Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K & Sadda SR & Beckman Initiative for Macular Research Classification Committee (2013): Clinical classification of age-related macular degeneration. Ophthalmology 120: 844-851.
    1. Finger RP, Fleckenstein M, Holz FG & Scholl HP (2008): Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools. Qual Life Res 17: 559-574.

LinkOut - more resources